Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAI-SHAN12: Phase Ib/II study of DZD8586-based combination therapy in diffuse large B-cell lymphoma
CTR20252152Phase 2Active
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of birelentinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Aug 2025; status: active.
02
Drugs
birelentinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20252152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252152.